Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

European Official Says COVID-19 Booster Uptake Disappointing In The Region

By Vandana Singh
Today, 11:02 AM
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather disappointing." The European average rate of receiving booster doses was only 29% in the groups considered to be at the highest risk.

AZN

Read More
1 minute read

Saudi Chemical Company Holding on Sunday Announced Signing a Collaboration Agreement with GlaxoSmithKline Consumer Healthcare Saudi Limited for Manufacturing in Saudi Arabia

By Charles Gross
Today, 11:02 AM
https://www.saudiexchange.sa/wps/portal/tadawul/home/announcement-details/!ut/p/z1/pZBLT4NQEIV_SxcsZQ6P4tXdlVoeIr6g0rsxYPCWhHIbihL_vUi7MVE0cXYz-b5kziFBGYkmf6tk3lWqyethXwvnKfYj1wczr5BcAvz6Jlzez0ODRaDHETBNlxlnNiIviE_B77i_Wq4SC55F4j8-7L_5-GE4fvfFiAS3nm0EA8IS5wI8daN4ET8YmDtHYCriJPCZYQQmngxJyFoVh8J5U1hMkmjLl7ItW_21Hc6brtvtzzVo6Ptel0rJutSf1VbDd8pG7TvKvpK026Zphio4EcV7z2ezD07fh48!/dz/d5/L0lDU0lKQ2dwUkNpQ2

GSK

Read More
2 minute read

GSK Announced Phase IIa Study Results for a New First-in-class Candidate Medicine for Patients With Tuberculosis Showed Early Bactericidal Activity With Low, Once-daily Oral Dose After 14 Days of Treatment in Users With Drug-susceptible Pulmonary TB

By Charles Gross
Today, 11:02 AM
GSK plc (LSE/NYSE: GSK) today announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well tolerated and showed early bactericidal activity with a low, once-daily oral dose after 14 days of treatment in participants with drug-susceptible pulmonary tuberculosis.

GSK

Read More
3 minute read

Nasdaq, S&P 500 Futures Build On Inflation-Data Momentum But Analyst Warn ‘Desperately Craved’ Rally May Not Sustain — Key Stocks To Watch Today

By Shanthi Rexaline
Today, 11:02 AM
Trading in the U.S. index futures points to the buying momentum extending into the final session of the week. The market may turn to the University Of Michigan's consumer sentiment report for trading cues, although profit-taking could take some sheen off the rally.

BABA

Read More
2 minute read

GSK Announced Blenrep DREAMM-3 Phase III Did Not Meet Primary Endpoint of Progression-free Survival

By Charles Gross
Today, 11:02 AM
GSK plc (LSE/NYSE: GSK) today announced that DREAMM-3, the phase III open-label, randomised head-to-head superiority trial of Blenrep (belantamab mafodotin) monotherapy versus pomalidomide in combination with low dose dexamethasone (PomDex) in patients with relapsed or refractory multiple myeloma (RRMM), did not meet its primary endpoint of progression-free survival (PFS).

GSK